A Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD).

Trial Profile

A Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD).

Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2016

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2012 Primary endpoint 'Conners-Adult-ADHD-Rating-Scale' has been met according to results presented at the 28th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
    • 07 Jun 2012 Results of primary endpoint presented at the 28th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
    • 04 Mar 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.(NCT00962104).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top